YL-202 is under clinical development by Suzhou Medilink Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YL-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YL-202 is under development for the treatment of solid tumors, advanced or metastatic non-small cell lung cancer and advanced or metastatic HR-positive and HER2-negative breast cancer (HER2- Breast Cancer), metastatic breast cancer, head and neck squamous cell carcinoma, colorectal cancer, HER2-positive gastric cancer, cervical cancer and ovarian cancer. The drug candidate is a antibody drug conjugate composed of human anti-HER3 antibody, protease-cleavable linker, and a novel topoisomerase I inhibitor. The drug candidate is administered through intravenous route.
Suzhou Medilink Therapeutics overview
Suzhou Medilink Therapeutics (Suzhou Medilink) is a biotech company focusing on antibody-drug conjugate research & development. Suzhou Medilink is headquartered in Suzhou, Jiangsu, China.
For a complete picture of YL-202’s drug-specific PTSR and LoA scores, buy the report here.